$BWXT

BWXT Looks 4.3% Undervalued on GF Value™

Guggenheim initiated coverage on BWX Technologies (BWXT) with a Buy rating and $192 price target, citing its strategic nuclear sector position. GF Value™ indicates BWXT is 4.3% undervalued at $148.53 vs. $155.28 intrinsic value. The company has a GF Score™ of 93/100, strong growth, and profitability but faces insider selling and premium valuation concerns.

Original reporting
Published Sep 15, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BWXT
Bullish
medium confidence
Mentioned
$BWXT
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BWXTBullishHigh
01

Why it matters

Analyst coverage may attract new capital, supporting price appreciation toward the target.

02

Market read

First analyst coverage of BWXT provides fresh investment thesis and price target, creating short‑term trading opportunity.

03

What to watch

Potential policy or funding changes for nuclear projects and supply-chain constraints.

Relevance 7/10Novelty 7/10Timing: today

Background

BWXT supplies naval nuclear reactors and commercial nuclear components, operating in a niche but growing sector.

Company-level read

Ticker impact

$BWXTBullishMedium confidence
Context

Guggenheim initiated coverage on BWXT with a Buy rating and a $192 price target, citing a 4.3% undervaluation.

Expected impact

potential price rise toward the $192 target over the next weeks

Evidence & confidence

Buy rating and target imply expected appreciation; however, high P/E and insider selling temper confidence.

Market effects

Positive signal for the nuclear industrial segment and defense contractors.

May boost investor interest in U.S. defense and energy stocks.

Highlights continued demand for nuclear propulsion, relevant to global energy transition.

Counterpoint

High P/E and recent insider selling could limit upside; valuation may be overstated.

Key entities

  • Guggenheim

    Initiated coverage with a Buy rating and $192 price target.

Related articles

$BWXTMed

Jim Cramer Favors BWX Technologies (BWXT) Over Cameco (CCJ)

Jim Cramer prefers BWX Technologies (BWXT) over Cameco (CCJ) for nuclear power investment, citing BWXT's stronger recent performance and Cameco's longer-term potential. BWXT reported Q2 revenue of $901.6M, up 18% YoY, and raised 2026 guidance. Cameco's Q2 uranium segment revenue fell to C$252M from C$352M YoY, but maintained production outlook. Both companies saw increased hedge fund interest.

$BWXTMed

Bwxt stock hits 52-week low at 146.1 USD

BWX Technologies Inc. (BWXT) stock hit a 52-week low of $145.91, down 40% from its high. Q2 2026 earnings beat estimates at $1.07 EPS, but revenue missed at $901.6M. Sales rose 18% YoY, and the company raised full-year free cash flow guidance to $345M-$360M. BWXT's backlog grew to $8.4B, up 40% YoY. Jefferies initiated coverage with a Buy rating, and Wells Fargo upgraded to Equal Weight.

$BWXTMed

Can BWXT's Canadian Lab Role Strengthen Nuclear Services Growth?

BWX Technologies (BWXT) is expanding its nuclear services through a new Canadian lab management role via a joint venture. The contract began in December 2025, complementing BWXT's broader strategy. The Kinectrics acquisition, completed in May 2025, is key to this expansion. BWXT's commercial revenues grew 62.8% YoY to $853.1M in 2025, with Kinectrics contributing $231M. Analysts expect EPS growth of 18.45% and 10.73% for 2026 and 2027, respectively.

$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.

$BWXTHighAI 8/10

BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock?

BWX Technologies (NYSE: BWXT) is the lowest-valued nuclear stock despite its monopoly in supplying nuclear reactors and fuel to the U.S. Navy. Its Q2 revenue rose 18% YoY to $901.6M, with EPS up 5% to $1.07. The company has an $8.6B backlog and raised its yearly revenue guidance to $3.8B. BWX also expanded into commercial markets, with Q2 commercial revenue up 72% YoY to $303M.

$BWXTMed

Expansion of Commercial Operations in Focus for BWX Technologies (BWXT)

Wells Fargo upgraded BWX Technologies (BWXT) to Equal Weight, lowering its target price to $170. The company reported Q2 2026 revenue of $901.6M, up from $764M last year, with adjusted EPS of $1.07. BWXT raised its full-year revenue guidance to $3.8B and adjusted EPS guidance to $4.70-$4.80. The stock is down 11.89% year-to-date. Management highlighted growth in commercial operations, while analysts noted risks related to revenue mix and leverage.